-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
BriaCell Therapeutics Corp. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q4 2021 to Q1 2024.
- BriaCell Therapeutics Corp. Earnings Per Share, Diluted for the quarter ending April 30, 2024 was 0.11 USD/shares.
- BriaCell Therapeutics Corp. Earnings Per Share, Diluted for the twelve months ending April 30, 2024 was -1.24 USD/shares.
- BriaCell Therapeutics Corp. annual Earnings Per Share, Diluted for 2023 was -1.3 USD/shares, a 24.9% increase from 2022.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)